Abstract:In pediatric age and particularly in newborn infants the drug efficacy and safety are influenced by the growth and development on drug Absorption, Distribution, Metabolism and Excretion (ADME). Thanks to the fast development of pharmacogenomics and pharmacogenetics, the drug therapy promises to be adapted to the genetic profile of the individual, reducing considerably the side effects of drugs and increasing their efficacy. Interindividual variability in drug response is well known in both adults and children. Such a variability is multifactorial considering both intrinsic and extrinsic factors. Drug distribution in the neonate is influenced by a variety of age-dependent factors as a total body water content and distribution variations, role of drug transporters, blood/tissue protein binding, blood and tissue pH and perfusion. The development of enzymes involved in human metabolism were classified in 3 categories: 1) those expressed during the whole or part of the fetal period, but silenced or expressed at low levels within 1-2 years after birth; 2) those expressed at relatively constant levels throughout fetal development, but increased to some extent postnatally; and 3) those whose onset of expression can occur in the third trimester, but substantial increase is noted in the first 1-2 years after birth. Besides this intrinsic aspects influencing pharmacokinetics during the neonatal period there are other important events such as inborn or acquired diseases, environment and finally pharmacogenetics and pharmacogenomics. Thousands of deaths every years are caused by fatal drug reactions; among the potential causes there are not only the severity of the disease being treated, drug interactions, nutritional status, renal and liver functions, but also the inherited differences in drug metabolism and genetic polymorphism. Adverse drug reactions (ADRs) among pediatric patients have been shown to be three times more frequent than in adults. On August 2010 The National Institute of Child Health and Human Development (NICHD) addressed patient safety issues in the NICU, recognizing that to understand and prevent adverse events, systematic research and education in safety issues needed. From all these concepts in terms of ADME, pharmacogenetics (relative to a single gene) and pharmacogenomics (relative to many genes) it is becoming more evident the perspective of the new concept of individualized medicine. The goal of this should be to identify which group of patients responds positively, which patients are nonresponders and who experiences adverse reaction for the same drug and dose. The interindividual variability in response to any drug is mostly dependent on DNA sequence variations across the human genome, the haplotype map (HAPMAP). At present there is still a big distance beween the knowledge in genetic and the practical application to model the drug profile to the genetic/genomic profile of the single patient. In the neonatal period the effects of growth in the pharmacodynamic, processes can help optimizing the dosage of neonatal frequently used medicines, thereby, minimizing their toxicity and increasing their efficacy. It should be useful to create accurate dosage adjustments according to the week of development.

Neonatal Clinical Pharmacology

Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates

Pharmacokinetic and pharmacodynamic principles: unique considerations for optimal design of neonatal clinical trials

Applied pharmacokinetics to improve pharmacotherapy in neonatal and paediatric intensive care units: focus on correct dose selection

Research of Neonatal Clinical Medication Should Be Highlighted

Drug related adverse event assessment in neonates in clinical trials and clinical care

Pharmacokinetic, efficacy, and safety considerations for the use of antifungal drugs in the neonatal population

Physiologically Based Pharmacokinetic Modeling in Neonates: Current Status and Future Perspectives

Potentially Harmful Excipients: State of the Art for Oral Liquid Forms Used in Neonatology and Pediatrics Units

Ontogeny and drug metabolism in newborns

Principles and Applications of Pharmacometrics in Drug Evaluation in Children.

Clinical Pharmacy Services in a Pediatric Emergency Room

Why population pharmacokinetic studies are instrumental to boost clinical research in neonates, and suggestions on how clinicians should assess these papers

Current Knowledge, Challenges and Innovations in Developmental Pharmacology: A Combined Conect4children Expert Group and European Society for Developmental, Perinatal and Paediatric Pharmacology White Paper

[Dosing regimens of antibiotics in neonates: Variations in clinical practice and what should be done?].

Optimal Sample Size for Use in Neonatal Pharmacokinetic Studies

Physiologically Based Pharmacokinetic Modeling in Pregnancy, during Lactation and in Neonates: Achievements, Challenges and Future Directions

Development and application of neonatal physiology‐based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment

Pharmacometric in silico studies used to facilitate a national dose standardisation process in neonatology – application to amikacin

Therapeutic drug monitoring in neonates

A Population and Developmental Pharmacokinetic Analysis to Evaluate and Optimize Cefotaxime Dosing Regimen in Neonates and Young Infants.